Appropriately Timed Intercourse

When it comes to fertility, timing can be everything. Most people know that a woman is able to conceive for only a short time each month. The question is, when—and for how long?

The best time to have sex

Fertility experts generally recommend that you have sex at least every other day just before and after you ovulate. This is because during ovulation, the egg that has matured in your ovary is released and settles into one of your fallopian tubes. After ovulation, this egg will survive for only about 24 hours. Sperm, however, can live up to five days in a woman's reproductive tract. 1

Assuming a woman has a 28-day cycle and that ovulation occurs around the 14th day of her cycle, her most fertile times would occur during days 10 to 17 of her cycle. But before you apply this math, remember: Not all women have 28-day cycles. The key to timing your intercourse is knowing the length of your own cycle so you can more accurately estimate when ovulation occurs. It's also important to understand that this "fertility window" can be highly unpredictable, even if a woman's menstrual cycle is usually regular.2

Ovulation Tools

Pinpointing the precise day when ovulation should occur is a bit of a challenge. There are several methods.

1. Charting your menstrual cycle. This is the easiest but least precise way to predict ovulation. Remember, a woman's cycle begins on the first day of her period and typically lasts about 28 days. The first day begins not when a woman is spotting, but when she experiences regular flow. In a 28-day cycle women may ovulate between days 10 and 17.

2. Taking your basal body temperature (BBT). To measure BBT, simply take your temperature every morning when you wake up. Chart the temperatures on a calendar. When you are ovulating, your BBT should rise about a half degree. Physical release of the ovum (egg) probably occurs on the day prior to the first temperature elevation.

3. Ovulation predictor kits. These kits work by measuring increases in your luteinizing hormone level just before ovulation. These kits are available without a prescription at your local drug store. They're easy to use, and can usually predict ovulation 24 to 36 hours in advance.

Unfortunately, no method is perfect. For more information, talk to your healthcare provider.

  • 1. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation: effects on the probability of conception, survival of the pregnancy, and sex of the baby. NEJM. 1995;333;1517-1521.
  • 2. Wilcox AJ, Dunson D, Baird DD. The timing of the "fertile window" in the menstrual cycle: day specific estimates from a perspective study. Br Med J. 2000;321:1259-1262.

Get a Snapshot of Your Unique Fertility Situation.

Register for My Fertility LifeLines™ today and get a customized report about your fertility with our Fertility Assessment Tool.

Personal Stories

Hear from others who have gone through what you and your partner may be experiencing.
Watch videos

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

Important Considerations:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Considerations:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading